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Docetaxel is a taxane-derived chemotherapy drug that has been approved for treatment of
prostate cancer. While docetaxel is frequently used as a treatment for hormone-refractory
prostate cancer, a subset of patients either do not respond to this treatment or those that do
respond eventually become resistant to the drug over time. Resistance to docetaxel is complex
andmulti-factoral and further understanding of the cellular biochemistry underlying resistance
is vital to improve treatment efficacy. To identify proteins altered in the resistant phenotype,
three parental cell lines DU145, 22RV1 and PC-3, as well as their docetaxel resistant sub-lines,
were subjected to quantitative label-free LC-MS proteomic profiling. A total of 189 significant
(p < 0.05) protein abundance changes were identified in the DU145 resistant sub-lines, 254 in
the 22RV1 sub-lines, and 51 and 72 in the 8 and 12 nM resistant PC-3 sub-lines, respectively.
From these, 29 proteins demonstrated a significant (p < 0.05) fold change across two or more
resistant variants. These included proteins indicative of an epithelial-to-mesenchemyl transition
as well as altered heat shock response elements.
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1 Introduction
Prostate cancer is a leading cause of cancer-related mortality
in males, with approximately 33 720 deaths occurring in the
United States in 2011 [1,2]. This malignancy primarily affects
older men with the median diagnosis age being 68 years [3].
Initial prostate tumour growth is generally androgen de-
pendent and, where indicated, therapy consists of surgery,
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radiation and androgen ablation. Androgen ablation ther-
apy typically results in temporary tumour regression as a
result of apoptosis induction due to the loss of steroid, how-
ever, as the cancer progresses, it often switches to androgen-
independent growth, within 2–3 years, thereby becoming
refractory to further hormonal ablation [4]. This is known
as castration-refractory prostate cancer (CRPC). Despite the
lack of response to androgen ablation, the androgen receptor
(AR) continues to be expressed after progression to CRPC [5].
Therefore, mechanisms other than loss of AR expression are
thought to drive CRPC.
Docetaxel, a taxane chemotherapeutic, is approved for use
in the treatment of advanced prostate cancer [6–8]. It induces
apoptosis by binding to tubulin and stabilising microtubules
and was the first drug to show survival benefits in CRPC.
It is currently the most effective drug used in the treatment
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of CRPC [6, 9], showing modest survival benefits, with an
increase in median survival time of 2 months, compared to
other treatment regimens [6, 7]. However, docetaxel can dis-
play variable pharmacokinetics in patients with up to ten-fold
differences in drug clearance; reduced clearance of the drug
is associated with serious side effects such as neutropenia
[10, 11]. Lower severity side effects including fatigue, nau-
sea, vomiting and alopecia are also associated with docetaxel
treatment of CRPC [6].
CRPC patients treated with docetaxel eventually develop
docetaxel resistance. Although some patients have the option
of further docetaxel treatment after a treatment-free inter-
val, no standard therapy for docetaxel-resistant CRPC exists
[12]. Docetaxel resistance has been attributed to a number of
mechanisms, including low initial effectiveness in prostate
cancer cells [13], alterations in tubulin isotype expression [14],
and increased AKT signalling due to loss of PTEN [15]. Ele-
vated levels of proteins such as Bcl-2 [16], other anti-apoptotic
proteins [17], STAT1 [18], clusterin [19] and HSPs [20] also
contribute to resistance by decreasing the apoptotic response
of cells.
Biomarkers of disease and drug resistance are key tools
in the predicting progression or drug resistance in diseases
such as prostate cancer. Proteomics has been applied to the
discovery of mechanisms of drug resistance in cell line mod-
els and clinical samples [21] and has a critical role to play
in furthering our understanding of all aspects of prostate
cancer [22]. One of the best known markers of prostate can-
cer is the prostate-specific antigen (PSA), which is routinely
measured to aid in the detection of the disease. However,
elevated PSA levels are not specific to prostate cancer and
this can result in an initial false diagnosis [23]. This high-
lights the importance of the development and use of more
than one marker for diagnosis, evaluation of disease progres-
sion or drug resistance. In the case of prostate cancer, further
research is needed to identify signatures of disease progres-
sion and drug resistance. Advances in technology now al-
lows global quantitative analysis of drug resistance through
genomics, proteomics and metabolomics (amongst others).
This development has led to the routine use of MS as a quan-
titative tool in proteomics [24]. MS-based quantitative pro-
teomics has been applied to prostate cancer in identification
of new diagnostic markers [25, 26], disease progression [27]
and mechanisms of drug resistance [28]. To date, proteomic
that which focused on docetaxel resistance in CRPC have
analysed single docetaxel resistant sub-lines [28]. The aim of
this study was to survey proteins in multiple prostate cancer
cell lines to reveal common differences in protein expression
relating to docetaxel resistance, thereby hoping to identify
robust indicators of resistance that might also provide new
mechanistic insight. We used a label-free LC-MS approach
to compare two androgen-independent (PC-3, DU-145) cell
lines and one androgen-sensitive (22RV1) cell line to their
docetaxel resistant sub-lines (PC-3 D8, PC-3 D12, DU145-RD
and 22RV1-RD). Resistance in all three cell lines was asso-
ciated with alterations in microtubule-associated cytoskeletal
proteins, suggestive of epithelial-to-mesenchymal transition
(EMT), and changes to HSP levels.
2 Materials and methods
2.1 Materials
Formic acid purchased from Fluka (Buchs, Switzerland).
HPLC grade acetone, methanol, ACN, water, Tris(2-
carboxyethyl) phosphine (TCEP), Tris, iodoacetamide, NP-
40, sodium chloride, sodium deoxycholate, SDS and PBS
(tablets) were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Sequencing grade trypsin was from Promega (Madi-
son, WI, USA). Protease inhibitor cocktail tablets were from
Roche (Basel, Switzerland). Pre-cast minigels for 1DE were
purchased from Lonza (Basel, Switzerland).
Antibodies forHSP70 (ab47455), and theAR (ab9474)were
from Abcam (Cambridge, UK). GRP78 antibody (610978)
was from BD Transduction Laboratories (San Diego, CA,
USA). Vimentin (V4630) and Vinculin (V4139) were from
Sigma-Aldrich.K1C19 antibody (MAB3238)was fromChemi-
con/Millipore (Billerica,MA,USA). K1C18 antibody (sc-6259)
was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2 Cell culture
Human prostate cancer cell lines PC-3, DU-145 and 22RV1
were purchased from the American Type Culture Collec-
tion (ATCC) and maintained in RPMI-1640 medium sup-
plemented with 10% FBS, 50 U/mL penicillin/50 g/mL
streptomycin and 2 mM L-glutamine (Invitrogen, Carlsbad,
CA, USA). PC-3, DU145 and 22RV1 resistant sub-lines were
generated by treating with Docetaxel (Sigma, St. Louis, MO,
USA) as previously described [29]. A subset of cells were aged
alongside the resistant cells as an appropriate control (PC-3
Ag,DU145Agand22RV1Ag). In all subsequent experiments,
the resistant PC-3 cells are referred to as PC-3 D8 and PC-3
D12 (reflecting the final treatment doses), while the DU145
and 22RV1 resistant sub-lines are referred to as DU145 RD
and 22RV1 RD, respectively. The PC-3 Ag cells had an IC50
of 10 nM, the PC-3 D8 IC50 = 20 nM and the PC-3 D12
IC50 = 100 nM following treatment with Docetaxel [29]. The
DU145Ag cells had an IC50 of 1.7 nM, the DU145 RD IC50 =
183.3 nM, 22RV1 Ag IC50 = 4 nM and 22Rv1 RD IC50 = 277
nM. Biological replicates, for each cell line, were within 10
passages of each other, with age-matched parental cells har-
vested at the same passage as matching resistant derivative
cells. Cells were passaged for a minimum of 2 weeks in the
absence of docetaxel before any experiments were carried out.
2.3 Protein extraction
Due to the inherent variability of protein fractionation, it was
decided to analyse whole cell lysates to minimise differences
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between themultiple cell lines analysed. Cells were harvested
for LC-MS analysis, following five washes in PBS by scraping
into cold PBS. Approximately 3 × 106 cells were spun at 1000
× g, and the cell pellet snap frozen in liquid nitrogen.
The cell pellet was resuspended in lysis buffer (50 mM
Tris, pH 8, 150 mM NaCl, 2% NP-40, 0.5% sodium deoxy-
cholate and 0.1% SDS). Lysis of cells was also aided by three
freeze–thaw cycles in liquid nitrogen. Protein lysates were
clarified by centrifugation (16 000 × g, 40 min, 4C). Pro-
tein concentration was determined by BCA protein assay kit
(Pierce, Rockford, IL, USA).
2.4 Protein digestion
Samples were digested according to themethod of Duan et al.
[30]. Protein samples were reduced with 4 mM TCEP at 95C
for 5min and alkylated with 20mM iodoacetamide at 37C for
30 min. A total of 100 g of total cell lysate was precipitated
in 100% percent ice-cold acetone, added in two aliquots, the
first was 1:1 (v/v) protein solution:acetone and the second 1:8
initial protein solution:acetone. This was incubated overnight
at –20C and then centrifuged at 12 000 × g for 20 min at 4C.
A further 100 L of acetone was used to wash the pellet and
it was again centrifuged at 12 000 × g for 20 min at 4C. The
pellet was allowed to air-dry for 3 min.
Trypsin (in 50 mM Tris buffer, pH 8.5) was added at an
enzyme/substrate ratio of 1:50 (w/w). After the sample was
briefly (10 s) sonicated in a water bath sonicator, and the
solution was incubated at 37C and 120 rpm for 5 h in a New
Brunswick shaking incubator (Edison, NJ, USA). A second
aliquot of trypsin was added at an enzyme/substrate ratio
of 1:50 (w/w) and the mixture incubated at 37C overnight.
This was spun at 16 000 × g for 15 min and 75 L of the
supernatant dried down in a vacuum centrifuge.
2.5 MS
Digested samples were resuspended in 0.1% TFA (Fluka) in
2% ACN and analysed by nanoLC-MS/MS using an Ultimate
3000 system (Dionex) coupled to a nanospray LTQ Orbitrap
mass spectrometer (Thermo Fisher Scientific, Rockford, IL,
USA), using a linear ACN gradient from 0% to 65% ACN
(Sigma) over 180 min. Buffers used for nano LC separation
contained 0.1% formic acid as the ion pairing reagent. The
flow rate was 300 nL/min. The LTQ Orbitrap was operated
in data-dependent acquisition mode with Xcalibur software.
Survey scan MS data were acquired in the Orbitrap on the
300–2000m/zmass range with the resolution set to a value of
60 000 at 400 m/z. The five most intense ions per survey scan
were selected for MS/MS fragmentation and the resulting
fragments were analysed in the linear trap. Collision energy
was set to 35%. Dynamic exclusion was employed within 60
s. Full scan mass spectra were recorded in profile mode and
tandem mass spectra in centroid mode. Biological replicates
(n = 4) were analysed for each sample type.
2.6 Progenesis analysis
RAWfiles were analysed in Progenesis LC-MS software. This
software extracts quantitative information from MS1 data by
aligning each LC-MS run to a reference file. Results were
filtered based on statistical analysis. Any peptides with an
ANOVA score of p > 0.05 were eliminated.
The MS2 data for the remaining peptides was exported
and the resulting MGF file used to search the Swiss-
prot database (Release 2011_05) on the MASCOT server
(www.matrixscience.com) for protein identifications. The
Mascot parameters were (1) species, Homo sapiens, (2) al-
lowed number of missed cleavages, 1, (3) fixed modification,
carboxylmethyl, (4) variablemodifications, methionine oxida-
tion (5) peptide tolerance, ± 20 ppm, (6) MS/MS tolerance,
± 0.6 Da and (7) peptide charge, + 2, +3 and +4. Peptides
were also searched against a decoy database to determine the
false discovery rate (FDR).
The total number of unique peptides exported were 2143
(PC-3 versus PC-3 D8), 1481 (PC-3 versus PC-3 D12), 20 030
(DU145 Ag versus DU145 RD) and 30 425 (22RV1 Ag versus
22RV1 RD). Based on these, a total of 173 (PC-3 D8, FDR =
1.98%), 279 (PC-3 D12, FDR = 2.54%), 523 (DU145 RD, FDR
= 3.82%) and 777 (22RV1 RD, FDR = 2.24%) proteins were
identified. This was then further narrowed down based on a
mascot peptide scores.
Peptide identifications were imported into the Progenesis
software and assigned to thematching features. Peptide iden-
tifications with a Mascot score less than 40 were eliminated
and peptides were assigned to a protein. Protein scores were
based on ANOVA values with a cut off of p < 0.05. Proteins
with quantitative information from twoormorepeptideswere
considered as significant. Peptide conflicts occur when a pep-
tide is identified as present in more than one protein. These
were resolved by assigning the peptide to the protein with
the greater number of hits, a greater Mascot score or a lower
mass error; when conflicts could not be clearly resolved, the
peptide was excluded from the analysis.
2.7 Pathway analysis
A shortlist of proteins was compiled from proteins that
showed a change in abundance with a similar trend in two
or more docetaxel-resistant sub-lines. Protein function, reg-
ulation and interaction were investigated by analysing short-
listed proteins in Pathway Studio 8.0 [31]. This software was
used to build protein networks based on in silico literature
mining. When features of interest were identified the litera-
ture for that node was assessed.
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2.8 Western blotting
Protein samples were reduced in Laemmli buffer supple-
mented by 350 mM DTT for 10 min at 95C, prior to sep-
aration of 2.5–30 g of protein on a 7.5% precast minigel.
Proteins were transferred to a nitrocellulose membrane over
6min on the dry iBlot transfer system (Invitrogen). Themem-
brane was blocked with blocking solution (5% dry milk in
PBS) for 1 h at room temperature before incubation with
the primary antibody in 2.5% milk (in PBS) solution at
4C overnight. After two 10-min washes with blocking so-
lution, the membrane was incubated with HRP secondary
antibody for 1 h. A further two washes in blocking solution
was followed by two washes in PBS. Subsequently, the blot
was visualised by incubating the blot for 5 min with ECL
Plus Western Blotting Detection substrate (GE Healthcare,
Buckinghamshire, UK) and fluorescent emission captured
by scanning blots at 457 nm excitation, 520 nm emission
(PMT 450) on a Typhoon 9400 fluorescent scanner. Densit-
ometry was carried out by assessing band volume in Image-
Quant 5.2 software (Molecular Dynamics, GE Healthcare).
The protein of interest was then normalised to the house-
keeping protein -actin. Significance of abundance changes
was assessed by student t-test with a significance value cut
off of p < 0.05. All blots were assessed in three biological
replicates.
Additionally, 1D gels, on which 30 g of protein was re-
solved, were stained with colloidal coomassie stain (Sigma)
overnight and destained in 10% (v/v) methanol to assess pro-
tein loading of lysates from each cell line.
Figure 1. Global analysis of protein abundance changes. (A) Scatter plot of protein abundance changes, as determined by label-free LC-MS,
in PC-3 docetaxel resistant variants (D8 and D12), DU145 and 22RV1 docetaxel resistant variants (RD). Only changes detected in more than
one docetaxel resistant cell line were plotted. Fold changes were calculated on the log2 scale (y-axis). Proteins were arranged in order
of ascending log2(fold change) in the 22RV1 cell line and then the DU145 RD cell line (x-axis), which represented the greatest number of
changes present. (B) Graphical summary of interactions between short-listed proteins (A) as determined by literature mining (Pathway
Studio 8.0). Proteins are represented by red circles. Protein cellular location is represented as membrane, cytoplasmic (white area) or
nuclear (turquoise). Grey lines represent regulation of protein activity by direct interaction while purple lines represent protein binding.
HSP90AA1 = HSP90A, KRT19 = K1C19, KRT18 = K1C18, KRT8 = K2C8, HSPA8 = HSP71
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3 Results
3.1 Proteomic profiling of docetaxel-resistant cell
lines
A total of 189 significant (p < 0.05) protein abundance
changes were identified in the DU145 cell line, 254 in the
22RV1 cell line, and 51 and 72 in the 8 and 12 nM resistant
PC-3 variants, respectively, when compared to their sensi-
tive parental lines. A full list of protein abundance changes
detected for each cell line, as well as MS data is available
in Supporting Information Tables S1–S4. Global analysis of
these changes showed that a large number of proteins had
altered abundance in more than one cell line, see Fig. 1(A).
In the case of the two PC-3 docetaxel resistant variants (PC-3
D8 and PC-3 D12), the magnitude of the log2(fold change) is
related to the level of docetaxel resistance, as the more sen-
sitive PC-3 D8 cells consistently demonstrated smaller fold
changes.
3.2 Common changes
A short list consisting of 31 proteins present in less than
two cell lines, with concurrent changes, was compiled and
analysed by Pathway Studio 8.0; five proteins had inter-
actions with each other, with several regulating the activ-
ity of others by direct interactions (grey lines) while others
showed evidence of protein binding (purple lines; Fig. 1 B).
As expected, interactions were shown between HSP90 and
HSP71.
Seventeen proteins were identified with altered abun-
dance levels in all PC-3, DU145 and 22RV1 docetaxel re-
sistant sub-lines (Listed in Table 1). Of these proteins, four
displayed concurrent changes in protein abundance in do-
cetaxel resistant cells. HSP71 a 70 kDa HSP (increased
abundance), a cytokeratin (K2C8, decreased abundance),
D-3-phosphoglycerate dehydrogenase (SERA, decreased
abundance) and valyl-tRNA synthetase (SYVC, decreased
abundance).
Table 1. Eighteen proteins with a change in abundance in either PC-3 docetaxel resistant sub-lines and both DU145 RD and 22RV1 RD
sub-lines.
Uniprot entry Protein PC-3 D8 PC-3 D12 DU145 RD 22RV1 RD
Log2 Unique Log2 Unique Log2 Unique Log2 Unique
(fold change) peptides (fold change) peptides (fold change) peptides (fold change) peptides
ACTN4 Alpha-actinin-4 0.98 7 1.33 3 0.46 21 −0.65 9
ALDOA Fructose-
bisphosphate
aldolase A
0.66 2 −0.25 12 −0.41 3
C1TC C-1-Tetrahydrofolate
synthase,
cytoplasmic
−0.64 2 −1.45 8 0.20 10 −0.53 3
EF1D Elongation factor
1-delta
−1.31 4 0.23 9 −0.51 3
GRP75 Stress-70 protein,
mitochondrial
0.81 2 0.81 3 −0.23 20 −0.15 9
HSP71 Heat shock 70 kDa
protein 1A/1B
0.86 4 0.86 7 0.19 7 0.25 8
HSPB1 HSP beta-1 −1.86 5 −2.00 4 0.89 7 0.30 5
K2C8 Keratin, type II
cytoskeletal 8
−2.36 8 −0.92 9 −0.90 4
NUCL Nucleolin −0.85 3 −1.40 6 −0.16 18 0.21 5
PRKDC DNA-dependent
protein kinase
catalytic subunit
−3.83 2 −0.16 31 0.31 10
SERA D-3-Phosphoglycerate
dehydrogenase
−1.17 5 −1.58 4 −0.58 8 −1.49 7
SYVC Valyl-tRNA synthetase −1.62 3 −0.23 10 −0.39 5
TCPB T-Complex protein 1
subunit beta
−1.33 2 0.14 14 −0.33 8
TKT Transketolase −1.45 5 −0.36 14 0.20 2
CH60 60 kDa HSP,
mitochondrial
−0.90 5 −0.25 28 0.25 6
ENPL Endoplasmin −0.82 4 −0.18 26 0.20 13
EF2 Elongation factor 2 0.73 3 0.21 26 −0.25 9
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Figure 2. Validation of altered chaperone protein abundance. (A) Heat map of fold changes in all chaperone proteins identified as having
an altered abundance in docetaxel resistant cell lines, fold changes are calculated in log2 scale. Proteins are represented on the vertical axis
while values for each individual resistant cell line are on the horizontal axis. (B) Representative image of 30 g of whole cell lysate, of the
parental PC-3 cell line (Ag), both its docetaxel resistant variants (D8 and D12) and the parental cell lines DU145 (Ag) and 22RV1 (Ag) along
with the corresponding docetaxel resistant variants (RD), separated on a 7.5% 1D SDS-PAGE gel and stained with colloidal coomassie
protein dye to demonstrate relative protein loading. (C) Western blot validation of HSP-70 (of which hsp71 and HSP7C are isoforms), also
shown is the corresponding immunoblot for -actin, which acted as a loading control; 2.5 g of whole cell lysate from each cell line was
separated on a 7.5% SDS-PAGE gel and subsequently transferred to nitrocellulose membrane. Graphical presentation of (D) HSP70 and
(E) Grp78 fold changes in docetaxel-resistant cell lines. Values represent mean ± SD (n = 3), *a significant change with p < 0.05 (Students
t-test); fold change was calculated by comparing resistant variants to their respective parental cell line, following normalisation to -actin
based on densitometry measurements of band area, calculations carried out in Log2 scale. Significant changes in HSP-70 abundance was
detected in PC-3 D12, DU145 RD and 22RV1 RD docetaxel resistance cell lines, while Grp-78 demonstrated small but significant changes in
abundance in the PC-3 D12 (decreased), DU145 RD (decreased) and 22RV1 RD (increased) docetaxel resistant cells.
3.3 Validation of HSP alterations
Widespread changes in HSP levels were identified in all
docetaxel-resistant sub-lines (Fig. 2A). Of these, the HSP70
isoforms, HSP71 andHSP7C, had increased protein levels in
twoormore cell lines.Grp78, a regulator of endoplasmic retic-
ulum homeostatsis, showed differential changes in expres-
sion across three resistant sub-lines. Validation of changes
in the abundance of HSP70 and Grp78 was carried out by
Western blot. Significant changes in HSP70 protein levels
were confirmed in the PC-3 D12, DU145-RD and the 22RV1
sub-lines, with an increase of between 1.02 to 1.22 log2(fold
change) in protein abundance across the four sub-lines (Fig.
2D and E). Grp78 had significant changes in all cell lines;
PC-3 D12 (–0.35), DU145 RD (–0.556) and 22RV1 RD cells
(0.56, Fig. 2D and E).
3.4 Cytoskeletal changes
A large number of cytoskeletal proteins were identified as
having an altered abundance in docetaxel-resistant cells. A
number of these changes are consistent with EMT, namely
decreases in cytokeratin proteins and increases in vimentin
and vinculin. It should be noted that keratin proteins are a
common contaminant in MS experiments. Of the keratins
identified in our study, see Table 2, K1C19 and cytokeratin
7 are known to be common contaminants [32]. However,
all of the keratin proteins found to have altered abundance
in the docetaxel resistant cell lines are expressed in normal
prostatic tissue and prostate cancer cell lines ([33–35], EBI
Gene Expression Atlas and Human Protein Atlas [36]). To
fully confirm that these changes are not due to contamina-
tion, validation by another technique would be necessary.
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Table 2. Keratin proteins with an altered abundance in docetaxel resistant cell lines. Given are the number of unique peptides for quantifi-
cation, a mascot score for protein identification, log ratio change in protein abundance and ANOVA p values for the change. p <
0.05 is deemed significant.
Cell line Peptides Mascot score ANOVA (p)?? Log10 (fold change)
K1C18_HUMAN Keratin, type I cytoskeletal 18
PC-3 D8 5 616.92 1.42 × 10–04 −0.4456
PC-3 D12 6 631.45 9.19 × 10–07 −0.7275
DU145 RD 8 907.49 2.45 × 10–03 −0.1038
22RV1 RD - - - -
K1C19_HUMAN Keratin, type I cytoskeletal 19
PC-3 D8 2 202.52 4.46 × 10–05 −0.2989
PC-3 D12 6 487.95 4.13 × 10–05 −0.4166
DU145 RD - - - -
22RV1 RD - - - -
K2C7_HUMAN Keratin, type II cytoskeletal 7
PC-3 D8 - - - -
PC-3 D12 5 323.09 1.55 × 10–04 −0.3181
DU145 RD 2 1210.44 0.05 −0.0334
22RV1 RD - - - -
K2C8_HUMAN Keratin, type II cytoskeletal 8
PC-3 D8 3 203.1 1.20 × 10–03 −0.3385
PC-3 D12 8 510.32 2.93 × 10–05 −0.7118
DU145 RD 8 796.43 1.42 × 10–07 −0.2765
22RV1 RD 4 209.35 6.97 × 10–04 −0.2695
KRT81_HUMAN Keratin, type II cuticular Hb1
PC-3 D8 3 208.77 2.15 × 10–05 –0.3979
PC-3 D12 - - - -
DU145 RD - - - -
22RV1 RD - - - -
– No significant change in protein abundance detected.
So, our study validated two of these proteins by Western
blotting using different protein lysates than employed in the
LC-MS analysis. Consistent with the MS results, significant
decreases in protein abundance for cytokeratin protein 18
(K1C18) were identified in PC-3 D12 and DU145 RD sub-
lines. Similarly, cytokeratin 19 (K1C19) showed significant
decreases in protein abundance in the PC-3 D12 sub-line
(Fig. 3A). An additional decrease not identified by MS, in
the abundance of K1C19, was found by Western blot in the
DU145 RD sub-lines (Fig. 3A). Vinculin protein abundance
was also assessed and showed a significant increase in the PC-
3 D12 sub-line (Fig. 3A). E-cadherin and N-cadherin are well-
characterised markers of EMT, and additional Western blots
were carried out to assess levels of these proteins in the doc-
etaxel resistant cell lines. In both thePC-3D12 andDU145 cell
lines, E-cadherin levels were significantly decreased whereas
N-cadherin demonstrated increased expression in the PC-3
D8 and D12 cell lines. In the PC-3 D8 and D12 sub-lines, fur-
ther indications of EMT were present. In Fig. 3(B), a change
in morphology can be seen in the PC-3 D8 and D12 sub-
lines when compared to the age-matched (Ag) parental cell
line. However, nomorphological changes were evident in the
DU145 RD and 22RV1 RD sub-lines.
3.5 AR abundance
Pathway analysis showed that a number of the short-listed
proteins had interactions with or regulated the expression of
the AR. Hence, the expression of the AR in the docetaxel-
resistant sub-lines was investigated by Western blot. Inter-
estingly, there was increased expression of the AR in the
androgen-independent docetaxel-resistant cell line (signifi-
cant in PC-3D12 and theDU145RD) as opposed to no change
in protein abundance in the androgen-sensitive 22RV1 RD
cell line (Fig. 4A and B [37]).
4 Discussion
To identify markers and to further understand the mech-
anisms of docetaxel resistance, four docetaxel-resistant cell
lines were analysed by label-free LC-MS. Proteomic analysis
revealed a small subset of proteins that consistently change
with docetaxel resistance in a number of the cell lines. Val-
idation of a subset of the identified proteins by Western
blot confirmed the semi-quantitative findings of the LC-MS
analysis.
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Figure 3. EMT association with docetaxel
resistance. (A) Immunoblot comparison
of known EMT markers; vinculin, cytoker-
atin 18 (C1K18), cytokeratin 19 (C1K19), E-
Cadherin and N-Cadherin, in the parental
PC-3 cell line (Ag) and both its docetaxel re-
sistant variants (D8 and D12) as well as the
parental cell lines 22RV1 (Ag) and DU145
(Ag) along with the corresponding doc-
etaxel resistant variants (RD). A total of 30
g of protein transferred to membranes,
which were probed for known markers of
EMT and then probed for -actin, which
acted as a loading control. Vinculin has
increased abundance in the PC-3 D12 cell
line. C1K18 and C1K19 both demonstrate
decreased abundance in the PC-3 D12
and DU145 docetaxel resistant cell lines.
E-Cadherin abundance decreased signifi-
cantly in both the PC-3 D12 and the DU145
cell lines. While N-cadherin was only de-
tectable in the PC-3 cell lines and dis-
played increased expression in the PC-3
D8 and D12 docetaxel resistant variants.
(B) Cell images of parental and resistant
variants of PC-3, DU145 and 22RV1 cell
lines (20× magnification). Morphological
changes can be seen in PC-3 D8 and D12
docetaxel resistant cells.
Figure 4. Altered abundance of the androgen receptor (AR). (A)
Immunoblot analysis of the AR; in the parental PC-3 cell line
(Ag), both its docetaxel resistant variants (D8 and D12) and in the
parental cell lines DU145 (Ag) and 22RV1 (Ag) along with the cor-
responding docetaxel resistant variants (RD). Also shown is the
corresponding immunoblot for -actin, which acted as a load-
ing control. (B) Graphical presentation of AR log2(fold change)
in docetaxel resistant cell lines. Values represent mean ± SD
(n = 3), *a significant change with p < 0.05 (Students t-test),
fold change was calculated by comparing band area (normalised
to -actin) of resistant variants to their respective parental cell
line.
The approach taken by this study has identified four pro-
teins that show concurrent changes in protein abundance in
the docetaxel resistant cell lines examined. K2C8, a cytoker-
atin,was decreased in docetaxel resistant cells,HSP70, aHSP,
had increased abundance in docetaxel resistant cells; bothwill
be discussed in more detail with respect to cellular processes.
D-3-phosphoglycerate dehydrogenase (SERA) catalyses the
rate-limiting step of serine biosynthesis, 3-phosphoglycerate
into 3-phosphohydroxypyruvate. It is present in higher lev-
els in approximately 70% of estrogen receptor negative breast
cancers but has not been linked to prostate cancer or docetaxel
resistance previously [38]. Valyl-tRNA synthetase (SYVC)
catalyses the attachment of amino acids to their complemen-
tary tRNA. The changes to K2C8 and SERA concur with the
findings of Zhao et al., [28], while the changes to HSP70
and SYVC have not previously been associated with docetaxel
resistance in prostate cancer.
4.1 Epithelial-to-mesenchymal transition
EMT, the transition of cells from an epithelial to mesenchy-
mal phenotype, occurs during cancer progression and can
contribute to the migration and metastasis of cancer cells
[39–41]. EMT has been associated with docetaxel resistance
in breast cancer [42] and in resistance to other chemother-
apeutics [43, 44]. In this study, docetaxel-resistant sub-lines
exhibited widespread changes in protein markers of EMT
when analysed by LC-MS. Further analysis of EMT-associated
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markers by Western blot suggests the occurrence of EMT in
both the PC-3 D12 and the DU145 RD cell lines. This is
supported by morphological changes evident in the PC-3 do-
cetaxel resistant cell lines. Previous studies, such as those by
Zhao et al., [28] have also examined proteomic changes due
to docetaxel resistance in PC_3 resistant variants that have
a high level of resistance to docetaxel without any apparent
change in cellular morphology. Previously, it has been shown
that treating these PC-3 D12 and DU145 RD cells with do-
cetaxel induces NFB activation [29]. It has been suggested
that NFB activation is key to EMT [45], therefore induced al-
terations of NFB activity may suggest a mechanism for the
EMT induction in these cells. Further functional work will
be necessary to determine if EMT contributes to resistance
or is merely a manifestation of docetaxel-induced changes in
cytoskeletal proteins.
4.2 HSPs
HSPs act as molecular chaperones, aiding the folding of pro-
teins under normal conditions and play a key role in cellular
response to stress [46,47]. SinceHSPs have such a vital role in
protecting cells from damage and have such a wide range of
client proteins, they have become exciting drug targets in the
treatment of cancer [48–50]. Proteomic analysis of the three
docetaxel resistant sub-lines revealed increases in proteins
such as HSP90a and HSP70 in multiple cell lines. HSP90 is
frequently over-expressed in cancer cells, playing a protective
role by repairing damage induced by cytotoxic chemothera-
pies and preventing the degradation of mutated oncoproteins
[51]. HSP90 client proteins include a wide range of proteins
key to prostate cancer development and progression, such
the AR. Targeting HSP90 function with specific inhibitors
affects the stability and function of these proteins, as such
a number of HSP90 inhibitors are under development or in
clinical trails [52]. 17-AAG, a geldanamycin derivative, has
an effect on AR receptor status in vivo and has been shown
to delay the progression to castrate resistance in xenograft
models of prostate cancer [53, 54]. Grp78, a member of the
HSP70 family, is induced as a result of endoplasmic reticu-
lum stress. It is associated with the development of advanced
metastatic prostate cancer and poorer survival [55, 56]. Grp-
78 expression decreased in the androgen-independent PC-3
D12 and DU145 RD sub-lines but increased in the androgen-
sensitive 22RV1 RD line. The differential expression of Grp-
78 highlights the importance of examining proteins in mul-
tiple cell lines. HSP70 also known as HSP71 and HSPA1A
is at present in low levels in normal cells. It is rapidly in-
duced under conditions of cellular stress and prevents stress-
induced apoptosis [57, 58]. HSP70 (HSP71) is upregulated
in several docetaxel resistant cell lines. It and has previously
been implicated in resistance to cisplatin resistance and other
chemotherapeutic agents [59, 60]. Targeting HSP70 expres-
sion in animal and cell models of cancer has anti-tumour
effects [61, 62]. HSP70 abundance is increased in docetaxel
resistant cells. However, targeting a single HSP in isolation
may not be an effective treatment strategy, as many HSPs
have overlapping effects and associated functions. For ex-
ample, AAG-17 treatment induces HSP70 expression, which
may limit the effectiveness of this HSP90 inhibitor [63], Tar-
geting multiple HSPs in combination with existing thera-
pies may be a more effective treatment strategy that could
be applied to docetaxel resistant CRPC, and highlights the
need for further development of HSP inhibitor strategies and
pharmaceutical.
4.3 Docetaxel-resistant CRPC cells express higher
levels of the AR
The AR is expressed throughout prostate cancer progression
[64] and is expressed in the PC-3 and DU145 cell lines de-
spite the general belief that these cell lines are AR negative
[65]. Protein expression changes in docetaxel resistant cells,
identified by label-free LC-MS, were linked to AR regulation
and expression by additional bioinformatic analysis [66–69].
In this study, all cell lines, parental and docetaxel resistant,
expressed AR. In the androgen-independent docetaxel resis-
tant cell lines, PC-3 D12 and DU145 RD, AR expression was
increased when compared to parental cells. In docetaxel sen-
sitive cells, AR signalling is impaired by docetaxel treatment,
as nuclear localisation of the receptor is inhibited [70]. Fur-
ther work will determine if this inhibition of AR signalling is
present in docetaxel resistant cells, and contributes to their
growth, as it has been shown that in some CPRC cell lines
AR expression can affect growth [71].
Quantitative label-free LC-MS analysis may represent an
attractive tool for predictive biomarker discovery and/or aid
in the mechanistic understanding of phenotypic alterations
in cells, e.g. those associated with resistance, since it can be
used both to identify unknown proteins and provide compar-
ative quantitative information on their abundance. However,
proteomic analysis is limited to a subset of proteins that can
be identified and quantified. This study utilised complemen-
tary bioinformatic techniques to get a broader perspective
on the individual protein changes generated from the pro-
teomic analysis and thereby identify linkages and pathways
that might act as rational targets for evaluation. These path-
way and system targets may not have been identified using
alternative techniques that do not examine the interrelation-
ships of the findings. Based on the proteomic profiling of
docetaxel resistant prostate cancer cells, EMTmay have an as-
sociation with docetaxel resistance in prostate cancer. HSPs
have emerged as potential drug targets that warrant further
investigation in docetaxel resistant prostate cancer and our
analysis suggests that the development of docetaxel resis-
tance may be associated with increased AR expression in at
least some instances. Furthermore, this analysis has identi-
fied protein changes not limited to a single cell line, which
may act asmore robustmarkers of docetaxel resistance. These
include SERA, SYVC, HSP70 and K2C8, which have altered
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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expression in all the docetaxel resistant cell lines examined.
Further analysis will indicate if these proteins represent use-
ful biomarkers of resistance and/or targets for drug inter-
vention, which aid in improving docetaxel-based treatment
efficacy.
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